Article info
PDFEditorial
Lessons from tofacitinib in patients with cardiovascular risk factors: increased pulmonary embolism or isolated (thrombotic) pulmonary occlusion rates?
- Correspondence to Professor Thomas Dörner, Department of Medicine/Rheumatology and Clinical Immunology, Charite Universitatsmedizin Berlin, Berlin 10117, Germany; thomas.doerner{at}charite.de
Citation
Lessons from tofacitinib in patients with cardiovascular risk factors: increased pulmonary embolism or isolated (thrombotic) pulmonary occlusion rates?
Publication history
- Received August 27, 2020
- Revised September 7, 2020
- Accepted September 8, 2020
- First published September 22, 2020.
Online issue publication
May 12, 2021
Article Versions
- Previous version (12 May 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.